» Articles » PMID: 37679810

Transcriptional Immunogenomic Analysis Reveals Distinct Immunological Clusters in Paediatric Nervous System Tumours

Abstract

Background: Cancer immunotherapies including immune checkpoint inhibitors and Chimeric Antigen Receptor (CAR) T-cell therapy have shown variable response rates in paediatric patients highlighting the need to establish robust biomarkers for patient selection. While the tumour microenvironment in adults has been widely studied to delineate determinants of immune response, the immune composition of paediatric solid tumours remains relatively uncharacterized calling for investigations to identify potential immune biomarkers.

Methods: To inform immunotherapy approaches in paediatric cancers with embryonal origin, we performed an immunogenomic analysis of RNA-seq data from 925 treatment-naïve paediatric nervous system tumours (pedNST) spanning 12 cancer types from three publicly available data sets.

Results: Within pedNST, we uncovered four broad immune clusters: Paediatric Inflamed (10%), Myeloid Predominant (30%), Immune Neutral (43%) and Immune Desert (17%). We validated these clusters using immunohistochemistry, methylation immune inference and segmentation analysis of tissue images. We report shared biology of these immune clusters within and across cancer types, and characterization of specific immune cell frequencies as well as T- and B-cell repertoires. We found no associations between immune infiltration levels and tumour mutational burden, although molecular cancer entities were enriched within specific immune clusters.

Conclusions: Given the heterogeneity of immune infiltration within pedNST, our findings suggest personalized immunogenomic profiling is needed to guide selection of immunotherapeutic strategies.

Citing Articles

Advances in the Repurposing and Blood-Brain Barrier Penetrance of Drugs in Pediatric Brain Tumors.

Rechberger J, Toll S, Biswas S, You H, Chow W, Kendall N Cancers (Basel). 2025; 17(3).

PMID: 39941807 PMC: 11816256. DOI: 10.3390/cancers17030439.


Transcriptomics-based characterization of the immuno-stromal microenvironment in pediatric low-grade glioma.

Korner M, Spohn M, Schuller U, Bockmayr M Oncoimmunology. 2024; 13(1):2386789.

PMID: 39135890 PMC: 11318680. DOI: 10.1080/2162402X.2024.2386789.


Immunotherapy for pediatric low-grade gliomas.

Pollack I, Felker J, Frederico S, Raphael I, Kohanbash G Childs Nerv Syst. 2024; 40(10):3263-3275.

PMID: 38884777 DOI: 10.1007/s00381-024-06491-9.


Radio-pathomic approaches in pediatric neuro-oncology: Opportunities and challenges.

Familiar A, Mahtabfar A, Kazerooni A, Kiani M, Vossough A, Viaene A Neurooncol Adv. 2023; 5(1):vdad119.

PMID: 37841693 PMC: 10576517. DOI: 10.1093/noajnl/vdad119.


Pediatric Brain Tumours: Lessons from the Immune Microenvironment.

Yao B, Delaidelli A, Vogel H, Sorensen P Curr Oncol. 2023; 30(5):5024-5046.

PMID: 37232837 PMC: 10217418. DOI: 10.3390/curroncol30050379.

References
1.
Sharma P, Pachynski R, Narayan V, Flechon A, Gravis G, Galsky M . Nivolumab Plus Ipilimumab for Metastatic Castration-Resistant Prostate Cancer: Preliminary Analysis of Patients in the CheckMate 650 Trial. Cancer Cell. 2020; 38(4):489-499.e3. DOI: 10.1016/j.ccell.2020.08.007. View

2.
Batlle E, Massague J . Transforming Growth Factor-β Signaling in Immunity and Cancer. Immunity. 2019; 50(4):924-940. PMC: 7507121. DOI: 10.1016/j.immuni.2019.03.024. View

3.
Marquet J, Lasoudris F, Cousin C, Puiffe M, Martin-Garcia N, Baud V . Dichotomy between factors inducing the immunosuppressive enzyme IL-4-induced gene 1 (IL4I1) in B lymphocytes and mononuclear phagocytes. Eur J Immunol. 2010; 40(9):2557-68. PMC: 3001484. DOI: 10.1002/eji.201040428. View

4.
Racle J, de Jonge K, Baumgaertner P, Speiser D, Gfeller D . Simultaneous enumeration of cancer and immune cell types from bulk tumor gene expression data. Elife. 2017; 6. PMC: 5718706. DOI: 10.7554/eLife.26476. View

5.
Ye X, Xu S, Xin Y, Yu S, Ping Y, Chen L . Tumor-associated microglia/macrophages enhance the invasion of glioma stem-like cells via TGF-β1 signaling pathway. J Immunol. 2012; 189(1):444-53. DOI: 10.4049/jimmunol.1103248. View